Ghostbusters

I have seborrheic dermatitis, my doctor advised me not to use shampoos with parabens, sulfates and silicone components, the pH of the shampoo should be neutral. It helped me a lot. Try changing your daily shampoo.I am taking oral finasteride

It looks amazing! What is the price for a graft?

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound LLOQ, with the highest not exceeding 0.015 ng/mL. In preclinical studies, by degrading androgen receptor (AR) protein, GT20029 could block the shrinkage and miniaturization of hair follicles which was caused by the activation of AR signaling pathway. As the result, it prevented the hair from thinning, softening and falling out. GT20029 could also effectively inhibit sebaceous gland development and sebum secretion. With limited skin penetration, GT20029 could avoid high systemic exposure and achieve a better safety profile. The repeated pharmacodynamics studies in dihydrotestosterone (DHT)-induced mouse model showed that GT20029 significantly promoted hair growth, with statistical difference. The study of testosterone propionate (TP)-induced skin hamster flank organ acne model showed that GT20029 significantly inhibited enlargement of flank organ, with statistical difference. Dr. Youzhi Tong, founder, Chairman and Chief Executive Officer of Kintor Pharma, commented, “The positive U.S. Phase I top-line results of GT20029 in 123 subjects has shown a similar result with that of Phase I trial in China with 92 subjects enrolled. Both studies have demonsrtated the good safety and tolerability in MAD of GT20029. Alopecia affects about 1.6 billion people and acne affects about 0.72 billion people worldwide, there are huge unmet clinical needs. We will accelerate the initiation of Phase II clinical trial of GT20029, maintain our leading position in the development of topical PROTAC drug candidate globally. We believe that GT20029 would strengthen our market position in the dermatology area, together with our novel drug KX-826, to provide a diversified portfolio of therapies to patients with AGA or acne. ” About GT20029 GT20029 is a topical AR degrader developed by Kintor Pharma’s PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively. In August 2022, Kintor Pharma had completed the enrollment and dosing of subjects for its China Phase I clinical trial. In November 2022, Kintor Pharma announced the top-line results for its China phase I clinical trial. In October 2022, Kintor Pharma announced completion of subject enrollment and dosing in its U.S. Phase I clinical trial.

Hello. I also have seborrheic dermatitis and I had large yellow crusts that were on the scalp and itching. Now I have managed to drown it out, I use a zinc pyrithione shampoo once a week, other days I use a ph neutral shampoo. I drink vitamins AE. I also changed jobs because of which I was very nervous. I don't know which of this list helped me, but my dermatitis has greatly reduced and does not bother me.